{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:08:21Z","timestamp":1793830101191,"version":"4.6.1"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T00:00:00Z","timestamp":1736294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972896"],"award-info":[{"award-number":["81972896"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515010288"],"award-info":[{"award-number":["2019A1515010288"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012620"],"award-info":[{"award-number":["2021A1515012620"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-024-06036-3","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T23:17:26Z","timestamp":1736291846000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Modulating tumor-associated macrophages through CSF1R inhibition: a potential therapeutic strategy for HNSCC"],"prefix":"10.1186","volume":"23","author":[{"given":"Kaiting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyi","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Min","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-2197","authenticated-orcid":false,"given":"Tianrun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6613-2696","authenticated-orcid":false,"given":"Jing","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1075-7475","authenticated-orcid":false,"given":"Weiping","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"6036_CR1","unstructured":"International Agency for Research on Cancer. https:\/\/gco.iarc.fr. Accessed 21 06 2024."},{"issue":"3","key":"6036_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"6036_CR3","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/jnci\/djk179","volume":"99","author":"M Hashibe","year":"2007","unstructured":"Hashibe M, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. J Natl Cancer Inst. 2007;99(10):777\u201389.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"6036_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/hed.25383","volume":"41","author":"YA Lee","year":"2019","unstructured":"Lee YA, et al. Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population. Head Neck. 2019;41(1):92\u2013102.","journal-title":"Head Neck"},{"issue":"6","key":"6036_CR5","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/ijc.28643","volume":"135","author":"N Guha","year":"2014","unstructured":"Guha N, et al. Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. Int J Cancer. 2014;135(6):1433\u201343.","journal-title":"Int J Cancer"},{"issue":"6","key":"6036_CR6","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/S1470-2045(12)70137-7","volume":"13","author":"C de Martel","year":"2012","unstructured":"de Martel C, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607\u201315.","journal-title":"Lancet Oncol"},{"issue":"3","key":"6036_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1023\/A:1023699717598","volume":"14","author":"P Boffetta","year":"2003","unstructured":"Boffetta P, et al. Occupation and larynx and hypopharynx cancer: an international case-control study in France, Italy, Spain, and Switzerland. Cancer Causes Control. 2003;14(3):203\u201312.","journal-title":"Cancer Causes Control"},{"issue":"10","key":"6036_CR8","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1093\/aje\/kwm193","volume":"166","author":"N Guha","year":"2007","unstructured":"Guha N, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol. 2007;166(10):1159\u201373.","journal-title":"Am J Epidemiol"},{"issue":"7","key":"6036_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.6004\/jnccn.2020.0031","volume":"18","author":"DG Pfister","year":"2020","unstructured":"Pfister DG, et al. Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(7):873\u201398.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"6036_CR10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.mayocp.2015.12.017","volume":"91","author":"S Marur","year":"2016","unstructured":"Marur S, Forastiere AA. Head and neck squamous cell carcinoma: update on epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2016;91(3):386\u201396.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"6036_CR11","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1111\/odi.12095","volume":"20","author":"E Brouns","year":"2014","unstructured":"Brouns E, et al. Malignant transformation of oral leukoplakia in a well-defined cohort of 144 patients. Oral Dis. 2014;20(3):e19-24.","journal-title":"Oral Dis"},{"issue":"19","key":"6036_CR12","doi-asserted-by":"publisher","first-page":"4912","DOI":"10.3390\/cancers13194912","volume":"13","author":"G Anderson","year":"2021","unstructured":"Anderson G, et al. An updated review on head and neck cancer treatment with radiation therapy. Cancers. 2021;13(19):4912.","journal-title":"Cancers"},{"issue":"12","key":"6036_CR13","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381(12):1124\u201335.","journal-title":"N Engl J Med"},{"key":"6036_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.critrevonc.2018.08.009","volume":"131","author":"G de Castro","year":"2018","unstructured":"de Castro G, et al. Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: consensus opinion from a panel of experts. Crit Rev Oncol Hematol. 2018;131:30\u20134.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"6036_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoto.2019.3550","volume":"146","author":"A Schuette","year":"2020","unstructured":"Schuette A, et al. Predicting hearing loss after radiotherapy and cisplatin chemotherapy in patients with head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2020;146(2):106\u201312.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"11","key":"6036_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-19-0214","volume":"18","author":"NF Saba","year":"2019","unstructured":"Saba NF, et al. Targeting the EGFR and immune pathways in squamous cell carcinoma of the head and neck (SCCHN): forging a new alliance. Mol Cancer Ther. 2019;18(11):1909\u201315.","journal-title":"Mol Cancer Ther"},{"issue":"10212","key":"6036_CR17","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394(10212):1915\u201328.","journal-title":"Lancet"},{"issue":"1","key":"6036_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78.","journal-title":"J Biomed Sci"},{"issue":"12","key":"6036_CR19","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/nrd.2018.169","volume":"17","author":"L Cassetta","year":"2018","unstructured":"Cassetta L, Pollard JW. Targeting macrophages: therapeutic approaches in cancer. Nat Rev Drug Discov. 2018;17(12):887\u2013904.","journal-title":"Nat Rev Drug Discov"},{"key":"6036_CR20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-pathmechdis-012418-012718","volume":"15","author":"M Locati","year":"2020","unstructured":"Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2020;15:123\u201347.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"6036_CR21","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"BZ Qian","year":"2010","unstructured":"Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141(1):39\u201351.","journal-title":"Cell"},{"issue":"7655","key":"6036_CR22","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"issue":"3","key":"6036_CR23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem JB, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013;73(3):1128\u201341.","journal-title":"Cancer Res"},{"issue":"20","key":"6036_CR24","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1200\/JCO.2008.19.9919","volume":"27","author":"TO Jensen","year":"2009","unstructured":"Jensen TO, et al. Macrophage markers in serum and tumor have prognostic impact in American joint committee on cancer stage I\/II melanoma. J Clin Oncol. 2009;27(20):3330\u20137.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6036_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","volume":"362","author":"C Steidl","year":"2010","unstructured":"Steidl C, et al. Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med. 2010;362(10):875\u201385.","journal-title":"N Engl J Med"},{"issue":"5","key":"6036_CR26","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-06-2073","volume":"13","author":"J Forssell","year":"2007","unstructured":"Forssell J, et al. High macrophage infiltration along the tumor front correlates with improved survival in colon cancer. Clin Cancer Res. 2007;13(5):1472\u20139.","journal-title":"Clin Cancer Res"},{"key":"6036_CR27","doi-asserted-by":"crossref","unstructured":"Donadon M, et al. Macrophage morphology correlates with single-cell diversity and prognosis in colorectal liver metastasis. J Exp Med. 2020.","DOI":"10.1084\/jem.20191847"},{"issue":"4","key":"6036_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jordao MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11(4):933\u201359.","journal-title":"Cancer Discov"},{"issue":"2","key":"6036_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41417-023-00704-0","volume":"31","author":"J Wu","year":"2024","unstructured":"Wu J, et al. SPP1(+) TAM subpopulations in tumor microenvironment promote intravasation and metastasis of head and neck squamous cell carcinoma. Cancer Gene Ther. 2024;31(2):311\u201321.","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"6036_CR30","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2326-6066.CIR-23-0595","volume":"12","author":"L Xu","year":"2024","unstructured":"Xu L, et al. ANXA3-rich exosomes derived from tumor-associated macrophages regulate ferroptosis and lymphatic metastasis of laryngeal squamous cell carcinoma. Cancer Immunol Res. 2024;12(5):614\u201330.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"6036_CR31","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1158\/0008-5472.CAN-13-1816","volume":"74","author":"S Mok","year":"2014","unstructured":"Mok S, et al. Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy. Cancer Res. 2014;74(1):153\u201361.","journal-title":"Cancer Res"},{"issue":"1","key":"6036_CR32","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.coi.2005.11.006","volume":"18","author":"V Chitu","year":"2006","unstructured":"Chitu V, Stanley ER. Colony-stimulating factor-1 in immunity and inflammation. Curr Opin Immunol. 2006;18(1):39\u201348.","journal-title":"Curr Opin Immunol"},{"issue":"11","key":"6036_CR33","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.tcb.2004.09.016","volume":"14","author":"FJ Pixley","year":"2004","unstructured":"Pixley FJ, Stanley ER. CSF-1 regulation of the wandering macrophage: complexity in action. Trends Cell Biol. 2004;14(11):628\u201338.","journal-title":"Trends Cell Biol"},{"issue":"6","key":"6036_CR34","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","volume":"25","author":"CH Ries","year":"2014","unstructured":"Ries CH, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846\u201359.","journal-title":"Cancer Cell"},{"issue":"8","key":"6036_CR35","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1158\/0008-5472.CAN-05-3523","volume":"66","author":"P Paulus","year":"2006","unstructured":"Paulus P, et al. Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. Cancer Res. 2006;66(8):4349\u201356.","journal-title":"Cancer Res"},{"issue":"1","key":"6036_CR36","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","volume":"1","author":"DG DeNardo","year":"2011","unstructured":"DeNardo DG, et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011;1(1):54\u201367.","journal-title":"Cancer Discov"},{"issue":"4","key":"6036_CR37","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41556-019-0298-1","volume":"21","author":"C Salvagno","year":"2019","unstructured":"Salvagno C, et al. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat Cell Biol. 2019;21(4):511\u201321.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"6036_CR38","doi-asserted-by":"publisher","first-page":"e005610","DOI":"10.1136\/jitc-2022-005610","volume":"10","author":"M Zhu","year":"2022","unstructured":"Zhu M, et al. Silence of a dependence receptor CSF1R in colorectal cancer cells activates tumor-associated macrophages. J Immunother Cancer. 2022;10(12):e005610.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"6036_CR39","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1093\/annonc\/mdz163","volume":"30","author":"CA Gomez-Roca","year":"2019","unstructured":"Gomez-Roca CA, et al. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced\/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol. 2019;30(8):1381\u201392.","journal-title":"Ann Oncol"},{"issue":"18","key":"6036_CR40","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu Y, et al. CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057\u201369.","journal-title":"Cancer Res"},{"issue":"4","key":"6036_CR41","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/neuonc\/noab228","volume":"24","author":"R Rao","year":"2022","unstructured":"Rao R, et al. Glioblastoma genetic drivers dictate the function of tumor-associated macrophages\/microglia and responses to CSF1R inhibition. Neuro Oncol. 2022;24(4):584\u201397.","journal-title":"Neuro Oncol"},{"issue":"21","key":"6036_CR42","doi-asserted-by":"publisher","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6036_CR43","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/s41467-023-37379-y","volume":"14","author":"HS Quah","year":"2023","unstructured":"Quah HS, et al. Single cell analysis in head and neck cancer reveals potential immune evasion mechanisms during early metastasis. Nat Commun. 2023;14(1):1680.","journal-title":"Nat Commun"},{"issue":"2","key":"6036_CR44","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s13402-023-00888-5","volume":"47","author":"J Liu","year":"2024","unstructured":"Liu J, et al. FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC. Cell Oncol (Dordr). 2024;47(2):623\u201338.","journal-title":"Cell Oncol (Dordr)"},{"issue":"8","key":"6036_CR45","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","volume":"20","author":"T Fujiwara","year":"2021","unstructured":"Fujiwara T, et al. CSF1\/CSF1R signaling inhibitor pexidartinib (PLX3397) reprograms tumor-associated macrophages and stimulates T-cell infiltration in the sarcoma microenvironment. Mol Cancer Ther. 2021;20(8):1388\u201399.","journal-title":"Mol Cancer Ther"},{"key":"6036_CR46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.bbi.2022.07.164","volume":"106","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice. Brain Behav Immun. 2022;106:49\u201366.","journal-title":"Brain Behav Immun"},{"issue":"5","key":"6036_CR47","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1056\/NEJMoa1411366","volume":"373","author":"WD Tap","year":"2015","unstructured":"Tap WD, et al. Structure-Guided Blockade of CSF1R Kinase in tenosynovial giant-cell tumor. N Engl J Med. 2015;373(5):428\u201337.","journal-title":"N Engl J Med"},{"issue":"10197","key":"6036_CR48","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","volume":"394","author":"WD Tap","year":"2019","unstructured":"Tap WD, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet. 2019;394(10197):478\u201387.","journal-title":"Lancet"},{"issue":"10","key":"6036_CR49","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/s43018-021-00254-0","volume":"2","author":"F Klemm","year":"2021","unstructured":"Klemm F, et al. Compensatory CSF2-driven macrophage activation promotes adaptive resistance to CSF1R inhibition in breast-to-brain metastasis. Nat Cancer. 2021;2(10):1086\u2013101.","journal-title":"Nat Cancer"},{"key":"6036_CR50","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-015-0281-z","volume":"35","author":"Y Hu","year":"2016","unstructured":"Hu Y, et al. Tumor-associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma. J Exp Clin Cancer Res. 2016;35:12.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"6036_CR51","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1038\/bjc.2014.446","volume":"111","author":"P Balermpas","year":"2014","unstructured":"Balermpas P, et al. Head and neck cancer relapse after chemoradiotherapy correlates with CD163+ macrophages in primary tumour and CD11b+ myeloid cells in recurrences. Br J Cancer. 2014;111(8):1509\u201318.","journal-title":"Br J Cancer"},{"issue":"12","key":"6036_CR52","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1002\/cncr.20701","volume":"101","author":"B Marcus","year":"2004","unstructured":"Marcus B, et al. Prognostic factors in oral cavity and oropharyngeal squamous cell carcinoma. Cancer. 2004;101(12):2779\u201387.","journal-title":"Cancer"},{"issue":"10","key":"6036_CR53","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.3337","volume":"19","author":"SM Pyonteck","year":"2013","unstructured":"Pyonteck SM, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264\u201372.","journal-title":"Nat Med"},{"issue":"12","key":"6036_CR54","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1158\/0008-5472.CAN-21-3714","volume":"82","author":"S Singh","year":"2022","unstructured":"Singh S, et al. Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Res. 2022;82(12):2281\u201397.","journal-title":"Cancer Res"},{"issue":"4","key":"6036_CR55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1093\/neuonc\/nov245","volume":"18","author":"N Butowski","year":"2016","unstructured":"Butowski N, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an ivy foundation early phase clinical trials consortium phase II study. Neuro Oncol. 2016;18(4):557\u201364.","journal-title":"Neuro Oncol"},{"issue":"9","key":"6036_CR56","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1158\/0008-5472.CAN-12-3981","volume":"73","author":"J Xu","year":"2013","unstructured":"Xu J, et al. CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer. Cancer Res. 2013;73(9):2782\u201394.","journal-title":"Cancer Res"},{"issue":"12","key":"6036_CR57","doi-asserted-by":"publisher","DOI":"10.4161\/onci.26968","volume":"2","author":"DC Strachan","year":"2013","unstructured":"Strachan DC, et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8(+) T cells. Oncoimmunology. 2013;2(12): e26968.","journal-title":"Oncoimmunology"},{"issue":"10","key":"6036_CR58","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","volume":"82","author":"YT Wei","year":"2022","unstructured":"Wei YT, et al. Thymosin alpha-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. Cancer Res. 2022;82(10):1991\u20132002.","journal-title":"Cancer Res"},{"issue":"11","key":"6036_CR59","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ccell.2023.09.014","volume":"41","author":"T Kerzel","year":"2023","unstructured":"Kerzel T, et al. In vivo macrophage engineering reshapes the tumor microenvironment leading to eradication of liver metastases. Cancer Cell. 2023;41(11):1892-1910 e10.","journal-title":"Cancer Cell"},{"issue":"2","key":"6036_CR60","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41590-022-01398-6","volume":"24","author":"S Ma","year":"2023","unstructured":"Ma S, et al. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8(+) T cells. Nat Immunol. 2023;24(2):255\u201366.","journal-title":"Nat Immunol"},{"issue":"8","key":"6036_CR61","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1158\/1535-7163.MCT-16-0866","volume":"16","author":"JY Ao","year":"2017","unstructured":"Ao JY, et al. Colony-stimulating factor 1 receptor blockade inhibits tumor growth by altering the polarization of tumor-associated macrophages in hepatocellular carcinoma. Mol Cancer Ther. 2017;16(8):1544\u201354.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"6036_CR62","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ymthe.2018.11.010","volume":"27","author":"G Shi","year":"2019","unstructured":"Shi G, et al. Modulating the tumor microenvironment via oncolytic viruses and CSF-1R inhibition synergistically enhances anti-PD-1 immunotherapy. Mol Ther. 2019;27(1):244\u201360.","journal-title":"Mol Ther"},{"issue":"11","key":"6036_CR63","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.3390\/cancers13112546","volume":"13","author":"SF Magkouta","year":"2021","unstructured":"Magkouta SF, et al. CSF1\/CSF1R axis blockade limits mesothelioma and enhances efficiency of anti-PDL1 immunotherapy. Cancers (Basel). 2021;13(11):2546.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"6036_CR64","doi-asserted-by":"publisher","first-page":"3146","DOI":"10.1158\/1078-0432.CCR-13-2576","volume":"20","author":"PP Patwardhan","year":"2014","unstructured":"Patwardhan PP, et al. Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res. 2014;20(12):3146\u201358.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-024-06036-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-024-06036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T01:03:24Z","timestamp":1736298204000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-024-06036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6036"],"URL":"https:\/\/doi.org\/10.1186\/s12967-024-06036-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5231239\/v1","asserted-by":"object"}]},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,8]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}